mehmet eren

Dr. mehmet eren

Marmara University
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2024 in JCO Global Oncology
Verified
Journal Article
Closed access
MSMutlay Sayan
Mutlay Sayan
AEAyfer Ay Eren
Ayfer Ay Eren
Yetkin TuaçYetkin Tuaç
Yetkin Tuaç
ALAstrid Langoe
Astrid Langoe
BABader Alali
Bader Alali
MEmehmet eren
mehmet eren
PURPOSE: Prostate cancer has emerged as a significant public health challenge in the Middle East, characterized by rising incidence rates and a concerning mortality-to-incidence ratio. Yet, despite these alarming trends, data regarding prostate cancer awareness in the region remain limited. To address this critical knowledge gap, this study investigates prostate cancer awareness within the Middle East. MATERIALS AND METHODS: A cross-sectional survey was performed among 5,913 men age 40 years and older across 14 Middle Eastern countries between January 1, 2022, and July 31, 2023. Excluding those with a history of prostate cancer, a validated questionnaire assessed prostate cancer awareness. Data were analyzed using frequencies and percentages for categorical variables, medians and ranges for continuous variables, and Pearson chi-square analysis for relationships between education levels and awareness of prostate cancer. RESULTS: The survey achieved a 74.9% response rate, with 4,431 male participants. Regarding prostate cancer awareness, 83.8% of participants had heard of the disease. However, only 31.0% correctly identified it as the most common malignancy in men, and 21.8% believed it affects both sex. Awareness of screening was limited, with just 19.1% recognizing the prostate-specific antigen test's role. Additionally, participants had a pessimistic view, with a mean perception that 75% of patients with prostate cancer die from the disease, rather than from other causes. Higher education levels were associated with significantly increased awareness of prostate cancer ( P < .001). CONCLUSION: This study reveals that while general awareness of the disease exists, crucial knowledge deficits regarding risk factors, screening, and prognosis are evident. Addressing these knowledge gaps through culturally tailored education may improve early detection rates, treatment outcomes, and ultimately reduce the burden of prostate cancer in the Middle East.

13 July 2020 in Medicina
Verified
Journal Article
Open access
PDF file
MEmehmet eren
mehmet eren
AEAyfer Ay Eren
Ayfer Ay Eren
MSMutlay Sayan
Mutlay Sayan
BYBirsen Yücel
Birsen Yücel
ŞEŞahende Elagöz
Şahende Elagöz
NBNuran Beşe
Nuran Beşe
Background and objectives: Everolimus (EVE) is a mammalian target of the rapamycin (mTOR) inhibitor that is widely used in cancer patients. Pulmonary toxicity, usually manifesting as interstitial pneumonitis, is a serious adverse effect of this drug. Radiation therapy, which is often administered in conjunction with chemotherapy for synergistic effects, also causes pulmonary fibrosis. In view of pulmonary damage development in these two forms of cancer treatment, we have examined the effect of EVE administration individually, in combination with radiation given in varying sequences, and its relation to the extent of pulmonary damage. Materials and Methods: We performed an experimental study in albino rats, which were randomized into five groups: (1) control group, (2) EVE alone, (3) EVE 22 h after radiation, (4) EVE 2 h after irradiation, and (5) only radiation. Sixteen weeks after thoracic irradiation, rat lung tissue samples were examined under light microscopy, and the extent of pulmonary damage was estimated. After this, we calculated median fibrosis scores in each group. Results: The highest fibrosis score was noted in Group 4. Among the five groups, the control group had a significantly lower median fibrosis score compared to the others. When the median fibrosis score of the group that received concurrent EVE with radiation therapy (RT) (Group 4) was compared with that of the control group, the difference was statistically significant (p = 0.0022). However, no significant differences were achieved among the study groups that received EVE only or RT only, whether concurrently or sequentially (p > 0.05). Conclusion: EVE is an effective treatment option for the management of several malignancies and is often combined with other therapies, such as radiation, for a more efficient response. However, an increased risk of pulmonary fibrosis should also be anticipated when these two modalities are combined, as they both can cause pulmonary damage, especially when administered concurrently.

13 March 2021 in Cureus
Verified
Journal Article
Open access
AEAyfer Ay Eren
Ayfer Ay Eren
MEmehmet eren
mehmet eren
SKSedat Koca
Sedat Koca
This study aimed to investigate changes in respiratory symptoms and quality of life (QoL) in patients with locally advanced and metastatic lung cancer receiving thoracic radiotherapy (RT). We investigated the correlation between the level of symptom relief and tumor response. Thirty-two patients were included in this study. The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QoL) Questionnaire (QLQ)-C30 and EORTC QLQ-LC13 were used to investigate QoL changes. Assessments were performed on the first day of RT, on the last day of RT, routinely monthly follow-ups, and three months after RT. The median age of the patients was 62; 88% of the patients were male. For the symptom scale, fatigue and dyspnea provided significant improvement at the end of RT (p=0.000, p=0.047). No significant improvement was observed at the end of RT in pain and insomnia. While coughing showed substantial improvement at the end of RT (p=0.004), the maximum improvement was achieved during the third-month follow-up (p<0.001). No significant improvement was observed at the end of RT in hemoptysis, but a considerable improvement was observed during the third-month follow-up (p=0.008). This study confirms that RT offered palliation of respiratory symptoms and improved QoL in a substantial proportion of patients with lung cancer.

21 August 2020 in Cureus
Verified
Journal Article
Open access
PDF file
MEmehmet eren
mehmet eren
DÖDidem Çolpan Öksüz
Didem Çolpan Öksüz
MSMutlay Sayan
Mutlay Sayan
SKSongül Karaçam
Songül Karaçam
IVIrina Vergalasova
Irina Vergalasova
FDFazilet Dincbas
Fazilet Dincbas
The aim of this study is to investigate the performance of kilovoltage (kV) cone-beam computed tomography (CBCT)-based adjustments with respect to kV-orthogonal fiducial marker-based matching in a group of patients with prostate cancer. Twenty prostate cancer patients were evaluated retrospectively: 10 with implanted fiducial markers and 10 without. Daily orthogonal kV imaging was recorded prior to radiation delivery. Images were evaluated in the left-right (LR), anterior-posterior (AP), and superior-inferior (SI) directions by matching either the implanted fiducials or going off bony anatomy, depending on the presence or absence of markers, respectively. Cone-beam computed tomography (CBCT) imaging was also subsequently acquired and images were aligned with the planning CT. The couch shifts were calculated and the patient’s position was adjusted accordingly. Standard deviations and random errors were also computed. Pearson correlation and Bland-Altman analysis were performed to evaluate relationships between the datasets. A total of 240 images were evaluated. The Pearson correlation coefficient for shifts applied to patients with markers using kV and CBCT was 88.3%, 87.8%, and 94.5% for the LR, AP, and SI directions, respectively. For those without markers, the respective values for the LR, AP, and SI directions were: 39.3%, 22.4%, and 3.7%. A Bland-Altman analysis comparing kV and CBCT in patients with markers, revealed R2 values of 0.152, 0.282, and 0.097 in the LR, AP, and SI directions, respectively. The R2 values for patients without markers were 0.008, 0.01, and 0.057, in the LR, AP, and SI directions, respectively. Our data suggest that CBCT can be a viable option for image-guidance in clinical settings where fiducial markers are unavailable such as situations of inaccessibility or medical contraindications.

1 September 2021 in Cancer Management and Research
Verified
Journal Article
Open access
PDF file
AEAyfer Ay Eren
Ayfer Ay Eren
MEmehmet eren
mehmet eren
Background: This study aimed to examine the practice patterns of radiation oncologists in Turkey regarding radiotherapy to the regional lymph nodes, including internal mammary lymph nodes (IMNs), and identify the factors influencing their clinical decisions in breast cancer patients. Methods: A nationwide, 19-point questionnaire was sent to the physician members of the Turkish Society for Radiation Oncology (TROD). Results: In total, 165 radiation oncologists completed the survey, corresponding to a 27% response rate. Regional radiotherapy was used in 64.2% of the patients with 1– 3 axillary lymphatic involvement and unfavorable prognostic factors. In contrast, 61.2% of the respondents indicated that IMN should be included in the target volume for regional radiotherapy when the patient had one positive node after axillary lymph node dissection (ALND) in the inner quadrant and central region tumors. However, 71.5% of the respondents chose to include the IMN in the non-inner quadrant and non-central region tumors for patients with four or more positive nodes after ALND. The decision to offer internal mammary lymph node radiotherapy (IMNRT) varied widely and significantly among respondents, years in practice, and the rates of dedicating their clinical time to patients with breast cancer. Conclusion: The results of this survey revealed significant national variation in attitudes regarding the treatment of IMN. Thus, this study may also help document the impact of future studies on clinical practice.

30 May 2022 in Marmara Medical Journal
Verified
Journal Article
Closed access
PDF file
AEAyfer Ay Eren
Ayfer Ay Eren
MEmehmet eren
mehmet eren
Objective: This study aimed to investigate survival and the response to radiotherapy (RT) among patients with molecular subtypes of breast cancer brain metastases. Patients and Methods: We retrospectively analyzed the data of 139 breast cancer patients with brain metastases treated with wholebrain radiotherapy (WBRT) or focal brain treatment (FBT) between 2006 and 2019. Overall survival (OS) and brain metastasis progression-free survival (BMPFS) were calculated from the first RT until death or the last follow-up. Survival analyses were performed using the Kaplan–Meier method. Prognostic factors were evaluated using the Cox proportional hazard model. Results: Twenty three (16.5%), 77 (55.4%), 14 (10.1%), and 25 (18%) patients were diagnosed with triple-negative, HER-2 (+), luminal-like A, and luminal-like B breast cancer, respectively. Of 139 patients, 66 (47.8%) underwent FBT, and 73 (52.5%) underwent WBRT. While the most preferred fraction was 10*300 Gy in WBRT, doses of 15-25 Gy in 1-5 fractions were preferred in local RT. We observed that age, Karnofsky performance scale (KPS) score, initial RT technique, extracranial disease, number of brain metastases impacted OS and BMPFS. Conclusion: Breast cancer brain metastasis is a different, complex, and challenging disease based on the molecular subtype of the tumor, despite various local treatments. Therefore, appropriate and tailored treatment approaches should be considered for the different molecular subtypes.